Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04724837 · ClinicalTrials.gov registry record · Phase 2
Zibotentan and Dapagliflozin for the Treatment of CKD (ZENITH-CKD Trial)
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 542
- Enrollment target
NCT04724837: Completed Phase 2 study, sponsored by AstraZeneca.
NCT04724837 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 542 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (308% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04724837, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 542 participants
- Enrollment target
Study Summary
The purpose of the study is to assess efficacy, safety and tolerability of treatment with zibotentan and dapagliflozin in combination and dapagliflozin 10 mg as monotherapy in participants with chronic kidney disease (CKD) with estimated glomerular filtration rate (eGFR) ≥ 20 mL/min/1.73 m\^2, and urinary albumin to creatinine ratio (UACR) ≥ 150 mg/g and ≤ 5000 mg/g.
Primary Outcome
The effect of zibotentan 1.5/dapagliflozin 10 mg versus dapagliflozin 10 mg on UACR was assessed.
Interventions
- DRUG Placebo
- DRUG Dapagliflozin
- DRUG Zibotentan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 542 participants |
| Start Date | 2021-04-28 |
| Est. Completion | 2023-06-01 |
| Phase | Phase 2 |
What the finished NCT04724837 record still lists
NCT04724837 is an interventional study that assigns participants to a tested intervention. The registered 542 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (308% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04724837 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04724837 about?
NCT04724837 is a clinical study titled "Zibotentan and Dapagliflozin for the Treatment of CKD (ZENITH-CKD Trial)". The purpose of the study is to assess efficacy, safety and tolerability of treatment with zibotentan and dapagliflozin in combination and dapagliflozin 10 mg as monotherapy in participants with chronic kidney disease (CKD) with estimated glomerular filtration rate (eGFR) ≥ 20 mL/min/1.73 m\^2, and u...
What is the current status of trial NCT04724837?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 542 participants. The study started on 2021-04-28. Estimated completion is 2023-06-01.
What interventions are being tested in trial NCT04724837?
The interventions under investigation include: Placebo (DRUG), Dapagliflozin (DRUG), Zibotentan (DRUG).
Who is sponsoring clinical trial NCT04724837?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04724837's enrollment target sits among peer trials
542 62nd of 2000 higher than 1,939 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04929223 · 542 participants · Phase 1
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
- NCT05584670 · 542 participants · Phase 1
A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors
- NCT07294053 · 543 participants · NA
Sugary Drink Labeling Study
- NCT03127761 · 544 participants
Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries With Multiple Myeloma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI